Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (61-70 of 221) with videos related to

Pageof 23
Sort By:
Clinical Genitourinary Cancer|January 22, 2013
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 TrialAurore Blesius, Benoit Beuselinck, Christine Chevreau, et al.
Clinical Genitourinary Cancer|May 18, 2016
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the LiteratureAmaury Daste, Marine Gross-Goupil, Amandine Quivy, et al.
Acta Oncologica (Stockholm, Sweden)|July 6, 2011
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitorsSophie Roca, Amandine Quivy, Marine Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2016
Targeted therapy and elderly people: A reviewAmaury Daste, Camille Chakiba, Charlotte Domblides, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2013
Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyAlain Ravaud, Shweta R Urva, Kai Grosch, et al.
Oral Oncology|October 23, 2018
Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinusMathieu Larroquette, Charlotte Domblides, Sophie Cousin, et al.
Oral Oncology|April 29, 2018
Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapyAmaury Daste, Erwan De-Mones, Valérie Cochin, et al.
Cancers|May 11, 2024
How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder CarcinomaMathieu Larroquette, Félix Lefort, Charlotte Domblides, et al.
Expert Opinion on Biological Therapy|April 5, 2020
Atezolizumab for the treatment of renal cell carcinomaMathilde Lafon, Charlotte Domblides, Amaury Daste, et al.
Cancers|December 23, 2022
Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every DecadeMathieu Larroquette, Félix Lefort, Luc Heraudet, et al.
Pageof 23

Showing results (61-70 of 221) with videos related to

Sort By:
Pageof 23
Clinical Genitourinary Cancer|January 22, 2013
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 TrialAurore Blesius, Benoit Beuselinck, Christine Chevreau, et al.
Clinical Genitourinary Cancer|May 18, 2016
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the LiteratureAmaury Daste, Marine Gross-Goupil, Amandine Quivy, et al.
Acta Oncologica (Stockholm, Sweden)|July 6, 2011
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitorsSophie Roca, Amandine Quivy, Marine Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2016
Targeted therapy and elderly people: A reviewAmaury Daste, Camille Chakiba, Charlotte Domblides, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2013
Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyAlain Ravaud, Shweta R Urva, Kai Grosch, et al.
Oral Oncology|October 23, 2018
Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinusMathieu Larroquette, Charlotte Domblides, Sophie Cousin, et al.
Oral Oncology|April 29, 2018
Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapyAmaury Daste, Erwan De-Mones, Valérie Cochin, et al.
Cancers|May 11, 2024
How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder CarcinomaMathieu Larroquette, Félix Lefort, Charlotte Domblides, et al.
Expert Opinion on Biological Therapy|April 5, 2020
Atezolizumab for the treatment of renal cell carcinomaMathilde Lafon, Charlotte Domblides, Amaury Daste, et al.
Cancers|December 23, 2022
Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every DecadeMathieu Larroquette, Félix Lefort, Luc Heraudet, et al.
Pageof 23